Voyager is eligible to receive $1.2 billion in milestone payments from Novartis as well as tiered royalties on global net sales of products incorporating Voyager’s TRACER capsids.
FDA OKs gene therapies from Vertex, Bluebird Bio for sickle cell disease
The FDA approved Vertex Pharmaceuticals’ Casgevy, which utilizes CRISPR/Cas9 technology, as well as Bluebird Bio’s Lyfgenia, a cell-based gene therapy that uses a lentiviral vector for genetic modification.
Sarepta’s Duchenne gene therapy fails primary endpoint, but company presses on
Sarepta Therapeutics’ Elevidys failed to meet its primary endpoint in a Phase 3 trial, shortly after the FDA granted it accelerated approval for Duchenne muscular dystrophy.
Regeneron, Intellia expand CRISPR-based research effort
In addition to the funding success, ElevateBio’s subsidiary Life Edit Therapeutics announced that it has signed a multi-target collaboration with Novo Nordisk.
Voyager plucks ex-Biogen CEO George Scangos out of retirement for board seat